Cargando…

Oncolytic Sendai virus-based virotherapy for cancer: recent advances

Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Saga, Kotaro, Kaneda, Yasufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918391/
https://www.ncbi.nlm.nih.gov/pubmed/27512677
http://dx.doi.org/10.2147/OV.S66419
_version_ 1782439115088723968
author Saga, Kotaro
Kaneda, Yasufumi
author_facet Saga, Kotaro
Kaneda, Yasufumi
author_sort Saga, Kotaro
collection PubMed
description Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Oncolytic viruses are one potential new anticancer strategy. Various oncolytic viruses have been developed for safe and effective oncotherapy. Recently, Sendai virus-based oncotherapy has been reported by several groups, and attention has been drawn to its unique anticancer mechanisms, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication. Here, we introduce Sendai virus-based virotherapy and its anticancer mechanisms.
format Online
Article
Text
id pubmed-4918391
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49183912016-08-10 Oncolytic Sendai virus-based virotherapy for cancer: recent advances Saga, Kotaro Kaneda, Yasufumi Oncolytic Virother Review Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development of new therapeutic technologies, in addition to new anticancer drugs, is necessary for more effective oncotherapy. Oncolytic viruses are one potential new anticancer strategy. Various oncolytic viruses have been developed for safe and effective oncotherapy. Recently, Sendai virus-based oncotherapy has been reported by several groups, and attention has been drawn to its unique anticancer mechanisms, which are different from those of the conventional oncolytic viruses that kill cancer cells by cancer cell-selective replication. Here, we introduce Sendai virus-based virotherapy and its anticancer mechanisms. Dove Medical Press 2015-10-01 /pmc/articles/PMC4918391/ /pubmed/27512677 http://dx.doi.org/10.2147/OV.S66419 Text en © 2015 Saga and Kaneda. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Saga, Kotaro
Kaneda, Yasufumi
Oncolytic Sendai virus-based virotherapy for cancer: recent advances
title Oncolytic Sendai virus-based virotherapy for cancer: recent advances
title_full Oncolytic Sendai virus-based virotherapy for cancer: recent advances
title_fullStr Oncolytic Sendai virus-based virotherapy for cancer: recent advances
title_full_unstemmed Oncolytic Sendai virus-based virotherapy for cancer: recent advances
title_short Oncolytic Sendai virus-based virotherapy for cancer: recent advances
title_sort oncolytic sendai virus-based virotherapy for cancer: recent advances
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918391/
https://www.ncbi.nlm.nih.gov/pubmed/27512677
http://dx.doi.org/10.2147/OV.S66419
work_keys_str_mv AT sagakotaro oncolyticsendaivirusbasedvirotherapyforcancerrecentadvances
AT kanedayasufumi oncolyticsendaivirusbasedvirotherapyforcancerrecentadvances